News & Event

October 2024

Global Action for Eye Health- World Sight Day 2024

The “Global Action for Eye Health” initiative focuses on worldwide efforts to enhance eye health and features inspiring stories of innovation and impact from around the globe. Watch the RevitalVision video created for this important initiative.

August 2024

RevitalVision has been awarded the winner of the VSP Vision Innovation Challenge

VSP Vision, the leader in delivering access to health-focused vision care, and MATTER, the premier healthcare incubator and innovation hub, announce RevitalVision as the winner of the first-ever VSP Vision Innovation Challenge.

June 24

RevitalVision on Israel21c

ISRAEL21C has interviewed Yair Yahav, CEO of RevitalVision about RevitalVision’s home-based vision training program.

The article beautifully illustrates how our simple home-based brain training technology greatly enhances vision and quality of life for our patients

June 2024

ESA-ISA 2024

We are thrilled to announce that Prof. Yair Morad will be presenting RevitalVision at the ESA-ISA 2024 Joint Meeting of the European and International Strabismological Associations, taking place in Toulouse France 13-15 June.

This event brings together the leading minds in pediatric ophthalmology, strabismus, orthoptic, and binocular vision, to share knowledge, exchange ideas, and explore the latest developments in these areas.
Professor Yair Morad will speak about Adult Amblyopia Treatment, sharing the latest clinical trial results withRevitalVision.

April 24

Improving Vision in Congenital Nystagmus – Pivotal RCT Results – AAPOS 2024

During the scientific program at AAPOS 2024 in Boston, Dr. Idan Hecht presented the groundbreaking findings from a prospective randomized controlled trial evaluating the efficacy of RevitalVision in improving vision in Congenital Nystagmus patients. the study demonstrated statistically significant improvement in distance and near BCVA, and significant improvement in stereo and binocular functions, offering new hope for nystagmus patients, lacking alternative solutions to improve vision.

April 2024

RevitalVision Post Crosslinking Surgery Study Won the Best ASCRS Scientific Poster Award

During the scientific program at ASCRS 2024, Prof. Lional Raj presented a new study on the efficacy of RevitalVisin on post-crosslinking surgery patients. His poster also won best scientific award.

This prospective, controlled randomized study evaluated the efficacy of RevitalVision’s software in improving best-corrected vision in stable keratoconus patients pos crosslinking surgery, and showed remarkable clinical outcomes.

Feb 2024

AECOS (American-European Congress of Ophthalmic Surgery)

RevitalVision’s CEO, Yair Yahav, participated in the 2024 AECOS innovation forum, which featured eight top industry innovations. The forum was moderated by Mr. William Link, PhD.

April 2023

AAPOS 23 annual meeting- presenting poster with mid term study results

During the 48th annual meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS 23), Dr. Sigal Zmujack’s presented the mid-term results of two new controlled randomized studies evaluating RevitalVision’s efficacy in improving vision in nystagmus and amblyopia patients aged 9-55, which both showed significant anti-suppression effects.

January 2023

Narayana Nethralaya Eye Foundation – What & how does my child see Conference

RevitalVision CEO Yair Yahav was a guest speaker at the Narayana Nethralaya Eye Foundation symposium on Amblyopia, Binocular Vision, Cortical Visual Impairment, and Low Vision.

He presented a scientific & clinical review on Optimizing Cortical Visual Functions with RevitalVision.

January 2023

A new published study on RevitalVision treatment

This independent study, which was published in Vision Development and Rehabilitation: COVD’s Digital Journal, evaluated the efficacy of RevitalVision’s perceptual-based vision training program, in improving visual acuity in adult amblyopic individuals beyond occlusion.

November22

Ophthalmology Innovation Source Summit (OIS)

Our CEO Yair Yahav presented at the OIS Israel (Ophthalmology Innovation Source Summit) during the MIXiii Health-Tech.IL conference between 9-10 November at the ICC in Jerusalem.

September 2022

Israel: A beacon of light helping with sight

This special feature article in GeekTime profiles innovative optics treatments and technologies from leading start-ups.

October 2022

Presenting at the ACADEMY 2022 SAN DIEGO

October 2022

October 2022 RevitalVision at EPOS 2022 Munich

September 2022

RevitalVision will present at ESCRS2022

We will be presenting at the 40th annual congress of The European Society for Cataract and Refractive Surgery (ESCRS) in Milan, Italy, from 16-19 September 2022.

March 2022

New randomized controlled trial on RevitalVision

Effects of Perceptual Learning on Deprivation Amblyopia in Children with Limbal Dermoid: A Randomized Controlled Trial.

The study compared 2 groups of children with amblyopia after corneal transplant : One group received standard patching therapy and the second group received patching + RevitalVision.

The group that underwent RevitalVision therapy experienced statistically significant improvement in vision.

March 2022

RevitalVision will present at the AAPOS 2022 – Arizona

2022 Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), on March 23-27, 2022.

March 2022

RevitalVision at HIMSS 22

This year, the Israel Export Institute together with the Foreign Trade Administration – Ministry of Economy & Industry will present 18Israeli Digital Health companies. And we are proud to be amongst these innovative companies

November 2021

RevitalVision on The Ophthalmologist

Yair Yahav, CEO and founder of RevitalVision, was interviewed in The Ophthalmologist about how we improve vision in adult amblyopia and other eye diseases and vision impairments

July 2021

RevitalVision received reimbursement code in the USA

RevitalVision is a standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age 9-plus), received a unique Current Procedural Terminology (CPT) reimbursement code from the American Medical Association (AMA).

3-6 November 2021

American Academy of Optometry Annual Meeting

We’re excited to be one of the exhibitors at the American Academy of Optometry Annual Meeting – which will be taking place in Boston

Visit us in the exhibit hall at booth #843

12-15 November 2021

AAO annual meeting

Come meet our experts at the AAO annual meeting, taking place in New Orleans this November

14/08/2020

RevitalVision recieves R&D grant from the Israeli Innovation Authority

01/08/2020

WSPOS – World Wide Webinar on Amblyopia – Sponsored by REVITALVISION

2020

A New Adult Amblyopia study presented at AIOS 2020 (All India Ophthalmology Society)

meeting 2020 confirming again the efficacy of RevitalVision in improving vision in adult amblyopia

2020

Tel Aviv Medical Center is recruiting Age related Macular Degeneration patients for a REVITALVISION clinical study

A Proof-of-Concept, Prospective, Open label, Randomized Clinical Study Evaluating RevitalVision® Therapy for Improving Best Corrected Visual Acuity (BCVA) and Contrast Sensitivity Function (CSF) in Patients Suffering from stabler Age related Macular Degeneration (AMD)

21-24 April 2021

REVITALVISION will participate at the upcoming 41st ESA (EUROPEAN STRABISMOLOGICAL ASSOCIATION)

Meeting in PARIS 21th /24th April 2021

7 October

REVITALVISION will participate at the upcoming AAOPT (AMERICAN ACADEMY of OOPTOMETRY)

Meeting in Nashville, TN, USA 7-10 October